Amgen (AMGN)
(Delayed Data from NSDQ)
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy
by Zacks Equity Research
Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.
Amgen Files for Approval of Osteoporosis Drug in Japan
by Zacks Equity Research
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.
Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.
Stock Market News for December 08, 2016
by Zacks Equity Research
The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
by Arpita Dutt
This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.
AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.
Amgen/Allergan File for EU Approval of Avastin Biosimilar
by Zacks Equity Research
Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.
Momenta/Shire's Humira Biosimilar Meets Study Objective
by Zacks Equity Research
Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.
Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
by Zacks Equity Research
Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
by Arpita Dutt
With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?
The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
Top Research Reports for Cisco, Amgen & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).
Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
by Eric Dutram
In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.
Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences
by Zacks Equity Research
Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
Fundamentals Remain Strong in the Pharma Sector
by Arpita Dutt
We could see several M&A agreements being announced in the coming quarters, though companies are wary of bidding wars leading to over-priced deals.
Pricing Issues Continue to Weigh on the Pharma Sector
by Zacks Equity Research
With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.
Pharma Industry Outlook - November 2016
by Arpita Dutt
It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.
Stock Market News for October 12, 2016
by Zacks Equity Research
Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday
6 Healthcare Stocks Investors Cannot Miss in Q3 Earnings
by Zacks Equity Research
A number of healthcare companies are recording improvements in their financial numbers.
Stock Market News for September 15, 2016
by Zacks Equity Research
Both the Dow and the S&P 500 closed in the red on Wednesday, thanks to a slump in crude-oil prices
Top Research Reports for September 2, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), HSBC (HSBC) and Broadcom (AVGO).
Stock Market News for August 09, 2016
by Zacks Equity Research
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks